Fly News Breaks for January 13, 2020
Jan 13, 2020 | 12:09 EDT
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $95 price target on Incyte following the company's agreement with MorphSys to license co-commercialization and development rights of tafasitamab. The deal, which does not affect MorphSys' ongoing trials, is costing Incyte $750M up front, which Van Buren believes is an "exceptionally reasonable upfront payment for Incyte, considering that the company is receiving an approvable drug that has multi-billion dollar sales potential." The analyst also noted that a tafasitamab BLA decision is expected mid-year 2020.
News For INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.